Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$18.2M | -$23.0M | -$31.9M | -$30.0M | -$20.5M | -$26.6M | -$27.6M | -$16.3M | -$65.1M | -$50.6M |
| Net income | -$18.1M | -$22.6M | -$31.5M | -$29.4M | -$27.3M | -$26.2M | -$27.3M | -$15.7M | -$62.9M | -$49.9M |
| EPS (diluted) | -$42.35 | -$3.04 | -$2.14 | -$1.20 | -$0.61 | -$5.89 | -$6.02 | -$3.42 | -$3.51 | -$1.96 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.0M | -$20.5M | -$27.9M | -$26.5M | -$20.5M | -$23.8M | -$24.9M | -$19.8M | -$22.3M | -$19.4M |
| Capital expenditures | — | $142K | $4.42M | $151K | $5.00K | $157K | — | — | — | — |
| Free cash flow | — | -$20.7M | -$32.3M | -$26.6M | -$20.5M | -$23.9M | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20.7M | $11.9M | $10.6M | $5.31M | $7.05M | $3.60M | $5.19M | $17.3M | $12.9M | $3.21M |
| Total assets | $22.0M | $52.7M | $30.3M | $26.5M | $16.3M | $48.5M | $22.0M | $106M | $62.2M | $24.2M |
| Total liabilities | $4.08M | $4.89M | $10.7M | $10.4M | $4.18M | $4.58M | $3.38M | $7.71M | $7.80M | $7.24M |
| Shareholders' equity | -$112M | $47.8M | $19.6M | $16.0M | $12.2M | $43.9M | $18.6M | $98.3M | $54.4M | $16.9M |
| Retained earnings | -$114M | -$137M | -$168M | -$198M | -$219M | -$245M | -$273M | -$289M | -$351M | -$401M |
| Shares (wtd avg diluted) | 432K | 14.7M | 14.7M | 27.8M | 43.8M | 4.44M | 4.54M | 4.60M | 17.9M | 25.4M |
Every figure is extracted from Rein Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.